17BHSD1

This program focuses on the development of small molecule hits targeting 17β-hydroxysteroid dehydrogenase (17β-HSD1), a key enzyme in the synthesis of estrogens (E2). The inhibition of 17β-HSD1 could be useful in the treatment of E2-dependent conditions such as endometriosis and cancer (breast or endometrial). This program is led by Dr. Poirier (Université Laval) who initially discovered and characterized these potent inhibitors. In parallel, a radioactive analog with potential as a diagnostic tool will be developed.